A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Exclusion Criteria

• •Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6 weeks
• •Steroid injection or intravenous (iv) infusion in the last 6 weeks
• •Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks
• •History of an inadequate response to a biologic disease-modifying anti-rheumatic drug (DMARD)
• •History of a serious reaction to other biological DMARDs
• •History of the use of rituximab or other B cell therapy
• •Use of DMARDS other than MTX, hydroxychloroquine, or sulfasalazine within the last 8 weeks
• •Use of leflunomide within the last 12 weeks (unless cholestyramine was used to speed up the elimination of leflunomide)
• •Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study
• •Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA
• •Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years
• •Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)
• •Hepatitis or human immunodeficiency virus (HIV)
• •A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months
• •Symptoms of herpes zoster or herpes simplex within the last month
• •Active or latent tuberculosis (TB)
• •Current symptoms of a serious disorder or illness
• •Use of an investigational drug within the last month
• •History of the use of rituximab, any other B cell targeted biotherapy, or denosumab